Oligonucleotide therapeutics are becoming increasingly popular, with scientists developing treatments for rare diseases, cancer, and respiratory disorders. To ensure their quality, researchers must ...

After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs and is making a strategic equity investment in Resalis Therapeutics Srl, providing ...

Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish ...

The webinar will address considerations when evaluating oligonucleotide synthesis reagent and solvent suppliers. Topics include scaling production during a global crisis; accessing manufacturing ...

A new partnership between technology innovation catalyst CPI, AstraZeneca, Novartis, and The University of Manchester will unite leading UK expertise in oligonucleotide synthesis as part of a mission ...

Researchers from Splisense Ltd. and affiliated organizations recently reported preclinical data for SPL-84, an inhaled antisense oligonucleotide drug candidate being developed for the treatment of ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and ...

Synoligo boosts production with new facility, expanding capacity for oligonucleotide synthesis. Since its establishment in July 2022, Synoligo has become a trusted partner in oligonucleotide ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

US FDA grants rare paediatric designation to ARTHEx Biotech’s ATX-01 for the treatment of myotonic dystrophy type 1: Valencia, Spain Friday, November 8, 2024, 16:00 Hrs [IST] AR ...